KRAS genetic variant as a prognostic factor for recurrence in resectable non-small cell lung cancer

被引:11
|
作者
Sullivan, I. [1 ]
Salazar, J. [2 ,3 ]
Arqueros, C. [1 ]
Andres, M. [1 ]
Sebio, A. [1 ]
Majem, M. [1 ]
Szafranska, J. [4 ]
Martinez, E. [5 ]
Paez, D. [1 ]
Lopez-Pousa, A. [1 ]
Baiget, M. [2 ,3 ]
Barnadas, A. [1 ,6 ]
机构
[1] Hosp Santa Creu & Sant Pau, Med Oncol Dept, Barcelona, Spain
[2] Hosp Santa Creu & Sant Pau, Genet Dept, St Antoni Maria Claret 167, Barcelona 08025, Spain
[3] CIBERER, U 705, Barcelona, Spain
[4] Hosp Santa Creu & Sant Pau, Pathol Dept, Barcelona, Spain
[5] Hosp Santa Creu & Sant Pau, Thorac Surg Dept, Barcelona, Spain
[6] UAB, Barcelona, Spain
来源
CLINICAL & TRANSLATIONAL ONCOLOGY | 2017年 / 19卷 / 07期
关键词
Resectable non-small cell lung cancer; Prognostic marker; VEGF pathway; KRAS; Genetic variants; ENDOTHELIAL GROWTH-FACTOR; PHARMACOGENETIC FACTORS; PATHWAY POLYMORPHISMS; VEGF POLYMORPHISMS; EXPRESSION; SURVIVAL; ANGIOGENESIS; CHEMOTHERAPY; ASSOCIATION; BEVACIZUMAB;
D O I
10.1007/s12094-017-1620-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Several angiogenic prognostic markers are under investigation because of their potential clinical utility, aiming to improve patient outcomes. We hypothesized that genetic variant in the VEGF pathway could be used as prognostic markers of survival in non-small cell lung cancer (NSCLC) patients undergoing pulmonary resection. Methods We evaluated the relationship between genetic variants in the VEGF pathway and relapse-free survival (RFS, main endpoint) and overall survival (OS, secondary endpoint) among 131 patients with stage I-III NSCLC treated with surgical resection from 2009 to 2013. Clinical, pathological and surgical data were prospectively collected. Twenty-five variants in sixteen relevant genes were selected and genotyped in tumor samples by real time PCR. The Kaplan-Meier method with the log-rank test and Cox's regression models were used for RFS and OS analyses. Results With a median follow-up of 36 (min = 2.8; max = 67.4) months, there were 31 (24%) relapses and 31 (24%) deaths. Overall, median RFS was not reached and median OS was 65 [95% confidence interval (CI) 56-75] months. The KRAS rs1137282 and PIK3C2A rs4356203 variants were significantly associated with RFS. For KRAS rs1137282, the 3-year RFS was 76% [95% CI 64-84%] in patients harboring an A/A genotype compared to 53% [95% CI 37-69%] in patients harboring an A/G or G/G genotype (p = 0.02). For PIK3C2A rs4356203, patients with an A/A or an A/G genotype had a 3-year RFS of 72% [95% CI 58-76%], whereas in patients with a G/G genotype was 49% [95% CI 28-70%] (p = 0.02). These associations remained statistically significant after adjusting for all the relevant clinical parameters in the multivariable analysis. Conclusion Genetic variants in VEGF pathway may be associated with recurrence in stage I-III NSCLC. Specifically, the KRAS rs1137282 could be considered as a prognostic factor for recurrence in resectable NSCLC patients. Although PIK3C2A rs4356203 was associated with RFS, further analyses are necessary to confirm these data.
引用
收藏
页码:884 / 890
页数:7
相关论文
共 50 条
  • [31] KRAS mutation, KRAS-LCS6 polymorphism, and non-small cell lung cancer
    Nelson, H. H.
    Christensen, B. C.
    Plaza, S. L.
    Wiencke, J. K.
    Marsit, C. J.
    Kelsey, K. T.
    LUNG CANCER, 2010, 69 (01) : 51 - 53
  • [32] Implementing circulating tumor DNA as a prognostic biomarker in resectable non-small cell lung cancer
    Abbosh, Chris
    Hodgson, Darren
    Doherty, Gary J.
    Gale, Davina
    Black, James R. M.
    Horn, Leora
    Reis-Filho, Jorge S.
    Swanton, Charles
    TRENDS IN CANCER, 2024, 10 (07) : 643 - 654
  • [33] Osteopontin is a prognostic biomarker in non-small cell lung cancer
    Rud, Ane Kongsgaard
    Boye, Kjetil
    Oijordsbakken, Miriam
    Lund-Iversen, Marius
    Halvorsen, Ann Rita
    Solberg, Steinar K.
    Berge, Gisle
    Helland, Aslaug
    Brustugun, Odd Terje
    Maelandsmo, Gunhild M.
    BMC CANCER, 2013, 13
  • [34] Current perspectives of KRAS in non-small cell lung cancer
    Harris, Ethan
    Thawani, Rajat
    CURRENT PROBLEMS IN CANCER, 2024, 51
  • [35] Targeting the KRAS Pathway in Non-Small Cell Lung Cancer
    Tomasini, Pascale
    Walia, Preet
    Labbe, Catherine
    Jao, Kevin
    Leighl, Natasha B.
    ONCOLOGIST, 2016, 21 (12): : 1450 - 1460
  • [36] Prognostic Factors for Patients With KRAS Mutated Non-Small Cell Lung Cancer and Brain Metastases
    Tsakonas, G.
    Skribek, M.
    Kamali, C.
    Zerdes, I.
    Johannsdottir, B.
    Ekman, S.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S599 - S599
  • [37] Prognostic significance of serum sMICA levels in non-small cell lung cancer
    Wang, L. -P.
    Niu, H.
    Xia, Y. -F.
    Han, Y. -L.
    Niu, P.
    Wang, H. -Y.
    Zhou, Q. -L.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2015, 19 (12) : 2226 - 2230
  • [38] The Prognostic Impact of Cigarette Smoking on Patients with Non-small Cell Lung Cancer
    Maeda, Ryo
    Yoshida, Junji
    Ishii, Genichiro
    Hishida, Tomoyuki
    Nishimura, Mitsuyo
    Nagai, Kanji
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (04) : 735 - 742
  • [39] Interleukins as new prognostic genetic biomarkers in non-small cell lung cancer
    Perez-Ramirez, Cristina
    Canadas-Garre, Marisa
    Alnatsha, Ahmed
    Angel Molina, Miguel
    Robles, Ana I.
    Villar, Eduardo
    Ramon Delgado, Juan
    Jose Faus-Dader, Maria
    Angel Calleja-Hernandez, Miguel
    SURGICAL ONCOLOGY-OXFORD, 2017, 26 (03): : 278 - 285
  • [40] Complement component 3 is a prognostic factor of non-small cell lung cancer
    Lin, Kailong
    He, Siyi
    He, Luhang
    Chen, Junyin
    Cheng, Xiaoming
    Zhang, Guoqiang
    Zhu, Bo
    MOLECULAR MEDICINE REPORTS, 2014, 10 (02) : 811 - 817